Interpace Biosciences, Inc.

About Us

Delivering Cutting-edge and Essential Insights

Interpace Biosciences (IDXG) is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics. Since our founding, we have helped physicians diagnose and treat more than 75,000 patients and have contributed to many of the most pivotal clinical trials in the pharmaceutical and biotech industries.

Interpace Diagnostics is a fully integrated commercial and bioinformatics company that provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services. We develop and commercialize molecular diagnostic tests that deliver cutting-edge genetic and mutational analysis. Our tests help risk-stratify patient samples for thyroid, pancreatic, lung, and other cancers to better inform treatment decisions.  

For pharmaceutical and biotech companies engaged in oncology-focused clinical trials, Interpace Pharma Solutions offers a comprehensive testing portfolio that can help better select candidate populations and reduce adverse drug reactions.  We provide seamless and dynamic coupling of comprehensive project life cycle management and full logistical support with the power of tested platforms for biomarker analysis, anatomic pathology, cytogenetics, and highly customized molecular technologies.  Interpace Pharma Solutions has deep knowledge and experience in designing, developing, and validating assays with biomarkers of clinical relevance for cancer diagnosis, prognosis, and theranosis.



Our Mission

Through our various business units, Interpace Biosciences works to improve patient care through personalized medicine driven by offering both molecular diagnostic tests supported by rigorous science and laboratory services supporting every phase of drug development. Via our unique combination of molecular diagnostic tests and laboratory services, healthcare providers will be able to avoid unnecessary surgeries and better assess risk of cancer progression in their patients, while pharmaceutical and biotech companies will be able to deliver safer, more effective compounds to market, and help both clinicians and researchers alike to fulfill the promise of personalized medicine.

Strong Research Collaborations

Interpace Biosciences has established strong research collaborations with key thought leaders in oncology and major cancer centers within the U.S. and abroad. These collaborations enable us to develop and validate proprietary tests in a clinical setting with the gained access to robust patient data. Interpace Biosciences’ abundant knowledge in oncology and vast testing capabilities allows for these proprietary tests to be tailored to the collaborators’ needs and specifications. Below is a summary of our active key collaborations.

Capabilities

Our molecular diagnostic tests and central laboratory services leverage the latest technology to deliver accurate results.

  • Predicting outcomes years down the road.
  • Determining whether a tumor is truly benign or malignant.
  • Combining Next Generation Sequencing and a miRNA classifier to deliver favorable positive and negative predictive values.
  • Early disease detection.
  • Multiple prognostic platforms to detect & evaluate the most aggressive cancers and diseases.
  • Clinical trial support services to deliver more personalized treatments to market
  • Custom assay development for companion diagnostics to aid in study design, study logistics, and data management

Our experienced pathologists and Ph.D.’s provide professional support for both the Diagnostics and Pharma Solutions teams.

Optimizing Value

We believe that molecular diagnostic testing represents strong patient value given the substantial opportunity it represents to lower healthcare costs by helping to reduce unnecessary surgeries and ensuring the appropriate frequency of ongoing monitoring that requires additional resources. In the era of high deductible and co-insurance plans, patients are taking on more and more responsibility for their own health care costs. Reducing unnecessary surgeries is another way Interpace Diagnostics’ products assist patients. 

Interpace Pharma Solutions is transforming global drug development with clinical trial solutions that will help identify more qualified target populations for clinical studies and optimize safety and efficacy of therapeutic compounds. The result is an overall improvement in Return on Investment, an important consideration in these days of escalating drug discovery and development costs.

Advancing Personalized Medicine

Our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. Interpace Diagnostics currently has five commercialized molecular diagnostic tests in the marketplace: PancraGEN®, ThyGeNEXT®, ThyraMIR®, RespriDX™, and BarreGen®.

As a responsive partner and reliable global provider of high-quality services, Interpace Pharma Solutions’ scientist driven solutions offer support for the spectrum of biomarker research to Phase III clinical trials and companion diagnostic development. We are uniquely positioned to deliver meet the needs of both healthcare providers and biopharma companies to empower personalized medicine disease management.

State-of-the-art, CLIA-certified Laboratories

All of Interpace Biosciences’ testing services are performed within our clinical reference laboratories located in Pittsburgh, PA, New Haven, CT, Rutherford, NJ, and Research Triangle Park, NC which have Clinical Laboratory Improvement Amendment (CLIA) certification and have been accredited by the College of American Pathologists (CAP).

Meet Our Team

Our success is largely attributed to the efforts of members of our skillful leadership team. As we continue to grow our molecular diagnostics business and develop and/or acquire additional molecular diagnostic tests, we will grow ever more reliant on their skills, experience, and performance.

View Management Team View Board of Directors